36C24924Q0314.docx
DOCX document 19 KB Posted
- Attached to
- 6505--Intent to Sole Source VISN Wide Radiopharmaceutical Pluvicto Blanket purchase agreement (BPA)
- Solicitation number
- 36C24924Q0314
About this file
This document is a Special Notice published by the Department of Veterans Affairs (VA), Network Contracting Office (NCO) 9, indicating their intent to award a sole-source Blanket Purchase Agreement (BPA) for the manufacture and delivery of Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a radioactive therapy treatment agent for prostate cancer, to Navartis Pharmaceuticals Corporation.
The BPA will have five ordering periods from 12/01/2024 to 11/30/2029, with estimated quantities ranging from 261 to 331 units per ordering period. The places of performance are listed as various VA medical centers in Tennessee and Kentucky. Interested parties may submit a capability statement, including their SAM UEI number, business information, and qualifications, by 06/27/2024 to be considered, but the government reserves the right to make a sole-source award without further competition if no responses are received.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| P09-SOW VISN 9 Pluvicto.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Special Notice Special Notice
| SUBJECT* |
| Intent to Sole Source VISN Wide Radiopharmaceutical Pluvicto Blanket purchase agreement (BPA) |
GENERAL INFORMATION
| CONTRACTING OFFICE’S ZIP CODE* |
| 37129 |
| SOLICITATION NUMBER* |
| 36C24924Q0314 |
| RESPONSE DATE/TIME/ZONE |
| 06-27-2024 10:00 am CENTRAL TIME, CHICAGO, USA |
| ARCHIVE |
| 90 DAYS AFTER THE RESPONSE DATE |
| RECOVERY ACT FUNDS |
| N |
| PRODUCT SERVICE CODE* |
| 6505 |
| NAICS CODE* |
| 325412 |
| CONTRACTING OFFICE ADDRESS |
| Department of Veterans Affairs |
Network Contracting Office 9 (90C)
NCO 9
1639 Medical Center Parkway, Suite 204 Murfreesboro TN 37129
POINT OF CONTACT*
Contract Specialist Christina Lawrence Christina.Lawrence2@va.gov 615-225-3426
ADDITIONAL INFORMATION
| AGENCY’S URL |
| https://www.va.gov/ |
| URL DESCRIPTION |
| Department of Veterans Affairs |
AGENCY CONTACT’S EMAIL ADDRESS
EMAIL DESCRIPTION
DESCRIPTION
INTENT TO SOLE SOURCE
This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 09, located at 1639 Medical Center Parkway, Suite 204, Murfreesboro, TN 37129 issuing an intent to award a single source blanket purchase agreement, five (5) ordering periods to Navartis Pharmaceuticals Corporation located at One Health Plaza, East Hanover, NJ 07936-1080 under FAR 13.106-1(b) and FAR 13.303 Blanket Purchase Agreements. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.
VISN 9 VA Medical Center requires manufacture and delivery of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) a radioactive therapy treatment agent indicated for prostate cancer treatment.
VISN 9 VA Medical Center estimated to purchase Pluvicto in quantities listed below:
| NDC# |
| Description |
| Estimated |
quantities
UI
| Ordering Period 1 |
| 69488-0010-61 |
| PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML |
| 261 |
| EA |
| Ordering Period 2 |
| 69488-0010-61 |
| PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML |
| 279 |
| EA |
| Ordering Period 3 |
| 69488-0010-61 |
| PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML |
| 298 |
| EA |
| Ordering Period 4 |
| 69488-0010-61 |
| PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML |
| 317 |
| EA |
| Ordering Period 5 |
| 69488-0010-61 |
| PLUVICTO :: LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML |
| 331 |
| EA |
See attached Statement of Work.
The Places of Performance are listed below:
James J. Quillen Veterans Affairs Medical Center Nuclear Medicine Dept Lamont Street & Veterans Way Johnson City, TN 37684
Tennessee Valley Healthcare System Nuclear Medicine Dept 1310 24th Avenue South Nashville, TN 37212
Alvin C. York Veterans Affairs Medical Center 3400 Lebanon Pike Murfreesboro, TN 37129
Troy Bowling Veterans Affairs Medical Center Nuclear Medicine Dept 1101 Veterans Drive Lexington, KY 40502
Lt. Col Luke Weathers Veterans Affairs Medical Center Nuclear Medicine Dept 116 N Pauline Street Memphis, TN 38105
Robley Rex Veterans Affairs Medical Center Robley Rex Veterans Affairs Medical Center Nuclear Medicine Dept HOT LAB Nuclear Medicine Dept HOT LAB 800 Zorn Avenue 4906 Brownsboro Road Louisville, Kentucky 40206-1499 Louisville, KY 40222
Estimated Period of Performance:
Ordering period 1: 12/01/2024-11/30/2025 Ordering period 2: 12/01/2025-11/30/2026 Ordering period 3: 12/01/2026-11/30/2027 Ordering period 4: 12/01/2027-11/30/2028 Ordering period 5: 12/01/2028-11/30/2029
Capability statement /information sought: Response to this announcement shall not to exceed 5 pages and should include the following information: (1) A tailored capability statement indicating the firm’s ability to provide a product and related services; (2) The respondents’ SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc,) pursuant to the applicable NAICS code; (3) Information should be provided electronically in a Microsoft Word or Adobe PDF format.
This notice of intent is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to the requirement and submit capability statement no later than 10:00 am., CT, Wednesday June 27, 2024 to: Christina.Lawrence2@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses received to this notice is solely within the discretion of the Government. If no written response is received within the closing date of this notice, a single source blanket purchase agreement award will be made to Navartis Pharmaceuticals Corporation without any further notice.
Disclaimer and Important Notes: This notice does not obligate the Government to award an agreement or otherwise pay for the information provided in response to this notice. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. However, responses to this notice will not be considered adequate responses to a notice.
See attached document: P09-SOW VISN 9 Pluvicto.
| *= Required Field |
| Special Notice |
Special Notice
File details come from the government source that posted it. Updated .